Loading…
Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.
Tongling-based biologic/personal-care technology company; specific product lines not independently confirmed.
Moat: none
Headquarters: Tongling, China · Employees: 647
Size Tongling Jieya Biologic Technology (301108.SZ) is a China Consumer Staples company (Household/Personal Care) with a market value of $961M, the 2374th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥39.98 on 6 Nov 2026.
Performance Over six months the shares gained 46.6%, against +1.4% for the median peer and -16.4% for the China market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 53.9% over the last twelve months (peer median +9.4%); the operating margin is 7.3% (peer median 9.9%).
Valuation It trades at 54.0× forward earnings against a peer median of 18.8× (most expensive of 21).
Capital Return on invested capital runs 1.2 points below its cost of capital (6.1% WACC).
Next results Next results expected around 15 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥881M | CN¥771M | CN¥546M | CN¥618M | CN¥664M |
| Revenue growth | — | +41% | -12% | -7% | — |
| Gross profit | CN¥203M | CN¥178M | CN¥94.9M | CN¥173M | CN¥203M |
| EBITDA | CN¥126M | CN¥130M | CN¥62.7M | CN¥136M | CN¥169M |
| Net income | CN¥86.3M | CN¥77.3M | CN¥19.5M | CN¥115M | CN¥141M |
| Free cash flow | -CN¥19.3M | -CN¥219M | CN¥20.7M | CN¥11.3M | CN¥282M |
| Capital expenditure | CN¥251M | CN¥368M | CN¥96.2M | CN¥85.1M | CN¥29.9M |
| Total debt | CN¥303M | CN¥172M | CN¥80.1M | CN¥105M | CN¥121M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301108.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.7% | +1.6% | 2nd lowest of 21 |
| 6-month return | +46.6% | +1.4% | highest of 21 |
| Distance from 52-week high | -29.3% | -28.7% | 11th highest of 21 |
| Revenue growth (TTM) | +53.9% | +9.4% | 3rd highest of 21 |
| Operating margin | 7.3% | 9.9% | 6th lowest of 21 |
| Forward P/E | 54.0× | 18.8× | most expensive of 21 |
| ROIC minus cost of capital | -1.2 pp | +6.3 pp | 4th lowest of 21 |
| EV / EBITDA | 43.4× | 10.2× | most expensive of 13 |
| Net debt / EBITDA | -7.4× | -0.4× | least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tongling Jieya Biologic Technology 301108.SZ | China | $961M | +47% | +54% | 7% | 54.0× | n/a | n/a |
| Noevir 4928.T | Japan | $977M | +3% | +1% | 16% | 19.4× | -4.8% | +4.5% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $944M | +15% | +10% | 11% | 28.9× | 4.3% | +10.8% |
| Runben Biotechnology 603193.SS | China | $940M | -33% | +13% | 21% | 18.9× | 1.7% | +28.4% |
| SYoung 300740.SZ | China | $1.00B | -37% | +14% | 3% | 39.6× | 18.1% | +6.1% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.06B | 0% | +74% | 18% | 12.1× | 11.5% | +49.0% |
| Galaxy Surfactants GALAXYSURF.NS | India | $819M | +13% | +30% | 9% | 18.6× | 18.0% | +13.7% |
| Cosmecca Korea 241710.KS | South Korea | $798M | +25% | +44% | 13% | 14.4× | -5.9% | +13.6% |
| Jyothy Labs JYOTHYLAB.NS | India | $773M | -23% | +5% | 8% | 30.9× | 35.0% | +8.9% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.22B | -52% | +23% | 8% | 15.0× | -5.9% | +21.2% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $750M | -19% | +10% | 6% | 17.7× | 4.7% | +7.7% |
| Edgewell Personal Care EPC | United States | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% | +2.7% |
| d'Alba Global 483650.KS | South Korea | $1.32B | -37% | +55% | 21% | 13.6× | -2.2% | +53.0% |
| Milbon 4919.T | Japan | $669M | +30% | +6% | 13% | 22.9× | -3.1% | +8.2% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |
| Intercos ICOS.MI | Italy | $1.50B | +16% | -5% | 9% | 19.5× | 4.5% | +11.5% |
| AMOREPACIFIC 002790.KS | South Korea | $1.55B | -3% | +9% | 9% | 8.4× | -17.9% | -1.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.58B | -30% | +28% | 20% | 22.5× | 8.7% | +3.6% |
| PZ Cussons PZC.L | United Kingdom | $566M | +30% | +5% | 11% | 13.3× | -1.7% | -2.1% |
| Energizer ENR | United States | $1.63B | +26% | +2% | 16% | 7.2× | -5.2% | +1.5% |